Predicting Successful Phase Advancement and Regulatory Approval in Multiple Myeloma From Phase I Overall Response Rates | JCO Clinical Cancer Informatics
Objective response rate of placebo in randomized controlled trials of anticancer medicines - eClinicalMedicine
Efficacy | BALVERSA® (erdafitinib) HCP
dMMR Recurrent or Advanced Solid Tumors | JEMPERLI (dostarlimab-gxly)
Efficacy Data | KYMRIAH® (tisagenlecleucel) for DLBCL | HCP
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Best Overall Response Rate (full analysis population) | Download Table
What Low Response Rates Mean for Telephone Surveys | Pew Research Center
Efficacy - Overall Response Rate | Aliqopa US HCP
Extremely High Objective Response Rate of Lenvatinib: Its Clinical Relevance and Changing the Treatment Paradigm in Hepatocellular Carcinoma | Semantic Scholar
Updated Data for Indoximod Plus KEYTRUDA® (pembrolizumab) Demonstrate Improvement of Response Rate for Patients with Advanced Melanoma | Business Wire
Objective response rate assessment in oncology: Current situation and future expectations
Comparing Outcomes in Patients with Recurrent or Refractory Ovarian Cancer Managed with 1 of 2 Versions of Pegylated Liposomal Doxorubicin at an Academic Medical Center
Clinical Trial Endpoints in Cancer Research: Four Terms You Should Know
Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in light chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris | BioSpace
Overall response rate | Download Table
Overall Response Rates - WM | IMBRUVICA® (ibrutinib) HCP
Overall Response Rate | CALQUENCE® (acalabrutinib) 100 mg tablets | For HCPs
Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults and Children | NEJM
Overall Response Rate of 76% in Advanced Melanoma Patients with Dynavax's SD-101 in Combination with KEYTRUDA® (pembrolizumab); Data Presented Today at the 2019 ASCO Annual Meeting | Dynavax Technologies Corporation
Durable Response Rate
Efficacy | BALVERSA® (erdafitinib) HCP
BRAFTOVI + cetuximab | Overall Response Rate | ORR | BEACON CRC
Cell therapy doubles survival, response rates in advanced melanoma
Zacks Small Cap Research - ONCS: New Data Provide Evidence that ImmunoPulse IL-12 Can Prime the Immune System
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial | Nature Medicine
